Status:

RECRUITING

Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia

Lead Sponsor:

Chinese University of Hong Kong

Conditions:

Colorectal Cancer

Colorectal Neoplasms

Eligibility:

All Genders

18-90 years

Brief Summary

The investigators hypothesize that gut microbiome composition and the four bacterial gene markers (M3) show dynamic changes after endoscopic resection of advanced neoplasia, some key bacteria are asso...

Detailed Description

Colorectal cancer (CRC) is one of the most common cancers in Hong Kong with more than 5,500 new cases annually. The majority of CRC cases are derived from benign colorectal adenomas through the proces...

Eligibility Criteria

Inclusion

  • Subjects require endoscopic resection (e.g. endoscopic mucosal resection or endoscopic submucosal dissection) for advanced adenoma or early-stage colorectal cancer;
  • Aged 18-90 years old;
  • Written informed consent obtained.

Exclusion

  • Absolute contraindications to colonoscopy (e.g. perforation, intestinal obstruction, unstable cardiopulmonary status);
  • Contraindications to endoscopic resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets);
  • Known pregnancy or lactation;
  • Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);

Key Trial Info

Start Date :

September 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 15 2024

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT05381792

Start Date

September 1 2022

End Date

December 15 2024

Last Update

August 27 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Prince of Wales Hospital

Shatin, New Territories, Hong Kong